A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2‐Year Results From the TENDER Trial

Background/Purpose: A phase 3 trial (TENDER) demonstrated the efficacy of the interleukin‐6 receptor inhibitor tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA) (). The aim of this study was to investigate the progression of radiographic joint damage in patients with s...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2014-03, Vol.66 (S3), p.S96-S97
Main Authors: Malattia, Clara, Ruperto, Nicolino, Palmisani, Elena, Pederzoli, Silvia, Pistorio, Angela, Brunner, Hermine, Cuttica, Rubén J., Calvo, Inmaculada, Garay, Stella Maris, Eleftheriou, Despina, Wouters, Carine, Wang, Jianmei, Devlin, Clare, Lovell, Daniel J., Martini, Alberto, Benedetti, Fabrizio, Ravelli, Angelo
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Purpose: A phase 3 trial (TENDER) demonstrated the efficacy of the interleukin‐6 receptor inhibitor tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA) (). The aim of this study was to investigate the progression of radiographic joint damage in patients with sJIA treated with TCZ for up to 2 years in TENDER. Methods: One hundred twelve patients 2 to 17 years old with active, refractory sJIA of ≥6 months' duration and inadequate response to previous nonsteroidal anti‐inflammatory drugs and oral corticosteroids were enrolled in TENDER. Patients were randomly assigned 2:1 to receive TCZ according to body weight (12 mg/kg
ISSN:2326-5191
2326-5205
DOI:10.1002/art.38482